Argenx, the Belgian-based biotech company, has recently signed a
$1.5 billion agreement with Unnatural Products to develop macrocyclic peptides as potential treatments for previously 'undruggable' diseases. Despite challenges in the past quarter that saw argenx’s shares fall,
analysts maintain bullish outlook. Particularly, Deutsche Bank upgraded its argenx price target citing robust performance. The U.S. FDA is currently assessing regulatory action regarding argenx's
Vyvgart Hytrulo amid severe worsening disease reports. Nonetheless, argenx forged ahead with the launch of the prefilled
Vyvgart syringe, followed by EC approval for both efgartigimod alfa and Vyvgart Hytrulo, along with an FDA nod for Vyvgart subcutaneous injection.
Q2 2025 marked a period of record growth and strategic advances for the biotech supporting forecasted growth in autoimmune disease innovations. argenx's investments in clinical development programs were highlighted with advances in ARGX-119 for Congenital Myasthenic Syndromes. Notably, Vyvgart sales nearly doubled to
$949 million suggesting major pipeline breakthroughs. Investors are closely monitoring argenx as its strong Q2 performance and positive outlook merit a strong buy rating.
argenx News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Thu, 07 Aug 2025 16:34:01 GMT -
Rating 8
- Innovation 7
- Information 7
- Rumor -6
